U.S. Markets closed
  • S&P Futures

    3,657.75
    +34.50 (+0.95%)
     
  • Dow Futures

    29,898.00
    +269.00 (+0.91%)
     
  • Nasdaq Futures

    12,390.75
    +113.75 (+0.93%)
     
  • Russell 2000 Futures

    1,843.50
    +23.40 (+1.29%)
     
  • Crude Oil

    45.00
    -0.34 (-0.75%)
     
  • Gold

    1,788.50
    +7.60 (+0.43%)
     
  • Silver

    22.98
    +0.39 (+1.71%)
     
  • EUR/USD

    1.1966
    +0.0031 (+0.2633%)
     
  • 10-Yr Bond

    0.8440
    +0.0020 (+0.24%)
     
  • Vix

    20.57
    -0.27 (-1.30%)
     
  • GBP/USD

    1.3354
    +0.0022 (+0.1656%)
     
  • USD/JPY

    104.4500
    +0.1260 (+0.1208%)
     
  • BTC-USD

    19,540.12
    +30.24 (+0.15%)
     
  • CMC Crypto 200

    383.39
    +18.79 (+5.15%)
     
  • FTSE 100

    6,266.19
    -101.39 (-1.59%)
     
  • Nikkei 225

    26,824.46
    +390.84 (+1.48%)
     

LAWSUITS FILED AGAINST FENC, COTY and BMRN - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS

·3 min read

NEW YORK, NY / ACCESSWIRE / October 28, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Fennec Pharmaceuticals Inc. (NASDAQ:FENC)

CONTACT JAKUBOWITZ ABOUT FENC:
https://claimyourloss.com/securities/fennec-pharmaceuticals-inc-loss-submission-form/?id=10515&from=1

Class Period: February 11, 2020 - August 10, 2020

Lead Plaintiff Deadline: November 2, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the manufacturing facilities for PEDMARK, the Company's sole product candidate, did not comply with current good manufacturing practices; (2) as a result, regulatory approval for PEDMARK was reasonably likely to be delayed; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Coty Inc. (NYSE:COTY)

CONTACT JAKUBOWITZ ABOUT COTY:
https://claimyourloss.com/securities/coty-inc-loss-submission-form/?id=10515&from=1

Class Period: October 3, 2016 - May 28, 2020

Lead Plaintiff Deadline: November 3, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) despite being no stranger to beauty brand acquisitions, Coty did not have adequate processes and procedures in place to assess and properly value the P&G Specialty Beauty Business and Kylie Cosmetics acquisitions; (2) as a result, Coty had overpaid for the P&G Specialty Beauty Business and Kylie Cosmetics; (3) Coty did not have adequate infrastructure to smoothly integrate and support the beauty brands that it acquired from P&G, including an adequate supply chain; (4) as a result of its inadequate infrastructure, Coty was not successfully integrating the beauty brands it acquired from P&G and not delivering synergies from the acquisition; and (5) as a result of the foregoing, Coty's financial statements and Defendants' statements about Coty's business, operations, and prospects, were materially false and/or misleading at all relevant times.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

CONTACT JAKUBOWITZ ABOUT BMRN:
https://claimyourloss.com/securities/biomarin-pharmaceutical-inc-loss-submission-form/?id=10515&from=1

Class Period: February 28, 2020 - August 18, 2020

Lead Plaintiff Deadline: November 24, 2020

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) differences between the Phase 1/2 and Phase 3 study of valoctocogene roxaparvovec, an investigational adenoassociated virus gene therapy, limited the reliability of the Phase 1/2 study to support valoctocogene roxaparvovec's durability of effect; (ii) as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law



View source version on accesswire.com:
https://www.accesswire.com/612829/LAWSUITS-FILED-AGAINST-FENC-COTY-and-BMRN--JAKUBOWITZ-LAW-PURSUES-SHAREHOLDERS-CLAIMS